Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice

This publication has 9 references indexed in Scilit:

• Characterization of recombinant and plant‐derived mistletoe lectin and their B‐chains
  European Journal of Biochemistry, 1999
• Cloning of the mistletoe lectin gene and characterization of the recombinant A‐chain
  European Journal of Biochemistry, 1999
• Expression of N-Acetyl Galactosaminylated and Sialylated Glycans by Metastases Arising from Primary Breast Cancer
  Invasion and Metastasis, 1998
• Immunophenotype of Human Ovarian Malignancies (Cystadenocarcinomata and Mixed Müllerian Tumor) Established in SCID Mice
  Experimental and Molecular Pathology, 1997
• Sialic Acids in Molecular and Cellular Interactions
  1997
• Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II and III with human breast cancer cell lines
  Glycoconjugate Journal, 1995
• Mistletoe treatment for cancer review of controlled trials in humans
  Phytomedicine, 1994
• Exploiting altered glycosylation patterns in cancer: Progress and challenges in diagnosis and therapy
  Trends in Biotechnology, 1994
• Evolution and pathophysiology of the human natural anti-?-galactosyl IgG (anti-Gal) antibody
  Springer Seminars in Immunopathology, 1993